LIDDS AB (publ)

DB:5LD Stock Report

Market Cap: €316.3k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

LIDDS Past Earnings Performance

Past criteria checks 0/6

LIDDS has been growing earnings at an average annual rate of 20.3%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been declining at an average rate of 36.8% per year.

Key information

20.33%

Earnings growth rate

39.41%

EPS growth rate

Biotechs Industry Growth-14.59%
Revenue growth rate-36.79%
Return on equity-373.79%
Net Marginn/a
Next Earnings Update26 Mar 2026

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How LIDDS makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:5LD Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 250-610
30 Jun 250-610
31 Mar 250-720
31 Dec 240-620
30 Sep 240-2230
30 Jun 240-2650
31 Mar 240-3180
31 Dec 230-40110
30 Sep 230-31140
30 Jun 231-34160
31 Mar 231-37160
31 Dec 222-37160
30 Sep 224-37150
30 Jun 224-36140
31 Mar 224-36130
31 Dec 214-37110
30 Sep 212-41100
30 Jun 211-40100
31 Mar 211-3580
31 Dec 200-3270
30 Sep 200-28-120
30 Jun 200-29-60
31 Mar 200-3210
31 Dec 190-3170
30 Sep 190-28240
30 Jun 198-15140
31 Mar 198-980
31 Dec 189-2140
30 Sep 188-110
30 Jun 181-860
31 Mar 181-730
31 Dec 171-730
30 Sep 171-730
30 Jun 170-710
31 Mar 170-730
31 Dec 160-730
30 Sep 160-660
30 Jun 160-660
31 Mar 160-770
31 Dec 150-880
30 Sep 150-880
30 Jun 150-880

Quality Earnings: 5LD is currently unprofitable.

Growing Profit Margin: 5LD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 5LD is unprofitable, but has reduced losses over the past 5 years at a rate of 20.3% per year.

Accelerating Growth: Unable to compare 5LD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5LD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (118.6%).


Return on Equity

High ROE: 5LD has a negative Return on Equity (-373.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/16 22:55
End of Day Share Price 2026/02/09 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LIDDS AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ethel Szpilman LuvallRedeye